Mainz Biomed's progress in colorectal cancer screening: a step forward in early detection Mainz Biomed has reported promising results in its efforts to improve the early detection of colorectal cancer (CRC), one of the leading causes of cancer-related deaths worldwide. The company's latest at-home screening test represents a major advancement in the early detection of CRC, utilizing cutting-edge Polymerase Chain Reaction (PCR) technology to identify molecular-genetic biomarkers in stool samples. In its European ColoFuture clinical study, Mainz Biomed reported a sensitivity of 94% and a specificity of 97% for the detection...